甘李药业：GLR1044注射液获临床试验批准

Core Viewpoint - Ganli Pharmaceutical has received approval from the National Medical Products Administration for its investigational drug GLR1044 injection, which is a biosimilar to Dupilumab, aimed at treating moderate to severe atopic dermatitis in adults [1] Group 1: Drug Approval - The National Medical Products Administration issued a clinical trial approval notice for GLR1044 injection, with acceptance number CXSL2500849 and notice number 2025LP03316 [1] - GLR1044 injection meets the registration requirements for drugs and is authorized to commence clinical trials [1] Group 2: Drug Indication - The drug is indicated for the treatment of moderate to severe atopic dermatitis in adults who have inadequate control with topical prescription medications or for whom topical prescription medications are not recommended [1] - GLR1044 can be used alone or in combination with topical corticosteroids [1]